Please wait while we load the requested 10-K report or click the link below:
Alexion Pharmaceuticals, Inc.
Sr. Director, Corporate Communications
Makovsky & Company
Mark Marmur (Media)
Rhonda Chiger (Investors)
Alexion Reports Fourth Quarter and Full Year 2009 Results
CHESHIRE, Conn., Feb 11, 2010 (BUSINESS WIRE) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN):
Soliris® Net Product Sales Increased 49% to $386.8 Million in 2009
Continued Strong Uptake of Soliris By New Patients in U.S. and Europe in Q4
Soliris Development Programs Advance in aHUS and Transplant
Fourth Quarter 2009 Financial Highlights:
Q4 2009 revenues increased 43% to $110.6 million, compared to $77.4 million in Q4 2008.
Q4 2009 GAAP net income was $237.1 million, or $2.59 per share, which includes $215.5 million from a non-recurring tax benefit. Excluding this one-time tax benefit, net income was $21.6 million, or $0.24 per share.
Q4 2009 non-GAAP net income increased to $28.5 million, compared to non-GAAP net income of $21.1 million in Q4 2008. Q4 non-GAAP earnings per share increased 35% to $0.31 per share, compared to $0.23 per share, in Q4 2008.
2009 Financial Highlights:
2009 revenues increased 49% to $386.8 million, compared to $259.1 million in 2008.
2009 GAAP net income was $295.2 million, or $3.26 per share, which includes $215.5 million from a non-recurring tax benefit. Excluding this one-time tax benefit, 2009 net income was $79.7 million, or $0.88 per share.
2009 non-GAAP net income increased to $108.4 million, compared to non-GAAP net income of $56.8 million in 2008. 2009 non-GAAP earnings per share increased 84% to $1.18 per share, compared to $0.64 per share, in 2008.
The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 11, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alexion Pharmaceuticals, Inc..